Eton Pharmaceuticals, Inc.
NASDAQCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- Sean E. Brynjelsen
- Full Time Employees
- 44
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Address
- 21925 W. Field Parkway Deer Park IL United States of America 60010-7278
- IPO Date
- Nov 14, 2018
- CIK
- 0001710340
- Website
- etonpharma.com
- Similar Companies
- Business
- Eton Pharmaceuticals, Inc. (ETON) is a specialty pharmaceutical company focused on developing, acquiring, and commercializing treatments for rare diseases, primarily targeting pediatric patients. The company offers six commercial rare disease products: INCRELEX (mecasermin), a biologic for severe primary insulin-like growth factor 1 deficiency in pediatric patients; ALKINDI SPRINKLE, hydrocortisone granules for pediatric adrenocortical insufficiency; PKU GOLIKE, a medical formula for phenylketonuria; Carglumic Acid for hyperammonemia due to N-acetylglutamate synthase deficiency; Betaine Anhydrous for homocystinuria; and Nitisinone for hereditary tyrosinemia type 1; along with GALZIN for Wilson Disease, which it plans to relaunch in the U.S. in early 2025. Founded in 2017 and headquartered in Deer Park, Illinois, Eton operates in the United States and Europe, sourcing therapies globally through partnerships and efficiently navigating FDA approvals to bring innovative medicines to underserved small patient populations. Recent developments include the December 2024 acquisition of INCRELEX from Ipsen, bolstering its pediatric endocrinology portfolio and now available exclusively through AnovoRx specialty pharmacy with Eton Cares patient support, alongside the acquisition of GALZIN to expand its metabolic disease offerings.
Company News
Connor Clark & Lunn Investment Management Ltd. Makes New $476,000 Investment in Eton Pharmaceuticals, Inc. $ETON
BlackRock Inc. Invests $68.63 Million in Eton Pharmaceuticals, Inc. $ETON
Eton Pharmaceuticals, Inc. $ETON Stock Holdings Increased by Bank of America Corp DE
Bank of Nova Scotia Acquires New Position in Eton Pharmaceuticals, Inc. $ETON
Eton Pharmaceuticals to Participate at 2026 Wells Fargo Healthcare Conference
Why Eton Pharmaceuticals Is Top of the Class Today
Eton Pharmaceuticals: No Reason Pharma Can't Deliver More Great Earnings Like These
Eton Pharmaceuticals, Inc. (ETON) Q2 2026 Earnings Call Transcript
Eton Pharmaceuticals Q2 Earnings Call Highlights
Eton Pharmaceuticals, Inc. (ETON) Q2 Earnings and Revenues Beat Estimates
Eton Pharmaceuticals Reports Second Quarter 2026 Financial Results
Bank of New York Mellon Corp Trims Stake in Eton Pharmaceuticals, Inc. $ETON
Eton Pharmaceuticals Expands Infantile Hemangioma Franchise with Acquisition of U.S. Rights to Late-Stage Product Candidate ASN-001
Eton Pharmaceuticals to Report Second Quarter 2026 Financial Results on Thursday, August 13, 2026
Eton Pharmaceuticals Announces Submission of Prior Approval Supplement to Expand Indication of KHINDIVI® (hydrocortisone) Oral Solution
Eton Pharmaceuticals (ETON) Moves 13.8% Higher: Will This Strength Last?
Eton Pharmaceuticals Inc (ETON) Shares Fall 4.3% -- What GF Score of 70 Tells Investors
Eton Pharmaceuticals Expands Rare Disease Portfolio Through Agreement for U.S. Commercialization Rights to IMPAVIDO® (miltefosine)
Eton Pharmaceuticals, Inc. (ETON) Q1 2026 Earnings Call Transcript
Eton Pharmaceuticals Q1 Earnings Call Highlights